Nature and duration of symptoms of cancers of the lung: report of a study of nature and duration of symptoms

Similar documents
Life after treatment for Lung Cancer

East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes. Dr Paul Beckett Royal Derby Hospital

LUNG CANCER. How to spot the signs and symptoms and reduce your risk. cruk.org

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD

Pneumonia. Pneumonia is an infection that makes the tiny air sacs in your lungs inflamed (swollen and sore). They then fill with liquid.

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Patient Electronic Alert to Key-worker System (PEAKS) Guidelines

Pregnancy and Tuberculosis. Patient and Public information sheet

Suspected pulmonary embolism (PE) in pregnant women

Personal Injury Intake Form

SAMPLE QUESTIONNAIRE

BRCA1 and BRCA2 for men

Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?

Survey to Doctors in England End of Life Care Report prepared for The National Audit Office

JSNA Factsheet Template Tower Hamlets Joint Strategic Needs Assessment

Goiter. This reference summary explains goiters. It covers symptoms and causes of the condition, as well as treatment options.

Radiotherapy for a mesothelioma

About lung cancer. Contents. The lungs

BREAST CANCER. How to spot the signs and symptoms and reduce your risk. cruk.org

If yes, you are not eligible to participate in this program)

TCH: Docetaxel, Carboplatin and Trastuzumab

Acknowledgement of Receipt of Notice of Privacy Practices

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

BACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes

Life, Critical Illness and Income Protection Claims Summary. From January to December 2013

NEW STUDENT SURVEY REPORT FOR FALL 2008 COHORT

Testing for Prostate Cancer

University College Hospital. Metastatic spinal cord compression (MSCC) information for patients at risk of developing MSCC.

The Radiotherapy Department Radiotherapy to the chest wall and lymph nodes

INFORMED CONSENT INFORMED CONSENT FOR PARTICIPATION IN A HEALTH AND FITNESS TRAINING PROGRAM

Introduction Hemophilia is a rare bleeding disorder in which the blood does not clot normally. About 1 in 10,000 people are born with hemophilia.

Prostate cancer statistics


Personal Injury Questionnaire

Take Steps to Control TB TUBERCULOSIS. When You HaveHIV

MEDICATION GUIDE STELARA

Pitcairn Medical Practice New Patient Questionnaire

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Thinking of getting pregnant?

Understanding Endometriosis - Information Pack

.org. Osteochondroma. Solitary Osteochondroma

Paclitaxel and Carboplatin

Louisiana Report 2013

Patient Case Information (Please Fill Out Forms Completely) (IF PATIENT IS UNDER 18 YEARS OF AGE LEGAL GUARDIAN MUST SIGN ALL PAPERWORK)

Symptoms of Hodgkin lymphoma

Optum Physical Health. Clinical Forms Instruction Manual

Patient Information. Medical History. Audiologic History

2010 National Survey. Newham University Hospital NHS Trust

Personal Training Health Screening Questionnaire

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

Culture and experience Health

Mesothelioma , The Patient Education Institute, Inc. ocft0101 Last reviewed: 03/21/2013 1

Inflammatory breast cancer

Lung cancer (non-small-cell)

What You Should Know About ASTHMA

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? Telephone

Radiation Oncology Patient information. Radiation Therapy for breast cancers

AC: Doxorubicin and Cyclophosphamide

Protect Your Family. and Friends from. The TB Contact Investigation TUBERCULOSIS

National Rheumatoid Arthritis Society

Utilization of Population Management Strategies

The link between cervical cancer and HPV (human papillomavirus)

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Liver Function Essay

Improving General Practice a call to action Evidence pack. NHS England Analytical Service August 2013/14

COI Research Management Summary on behalf of the Department of Health

Patient Satisfaction Survey Results 2011

Asbestos and your lungs

Bariatric Surgery. An Actuarial Perspective John Dawson, FSA, MAAA Senior Vice President and Actuary. February 27, 2009 DSL # AP

BRIEFING PAPER THE USE OF RED FLAGS TO IDENTIFY SERIOUS SPINAL PATHOLOGY THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. Version:

Thymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

Throughout this reference summary, you will find out what massage therapy is, its benefits, risks, and what to expect during and after a massage.

The National Survey of People with Diabetes

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

Substance misuse and TB: Information for families affected

A practical guide to understanding cancer. signs and symptoms. of cancer. what to be aware of

2 months Diptheria; Tetanus; Whooping Cough; Hib & Polio 1st dose Pneumococcal Conjugate Vaccination

How To Get A Membership At Angelina Rehabilitation Center

9 Expenditure on breast cancer

NEUROPSYCHOLOGY QUESTIONNAIRE. (Please fill this out prior to your appointment and bring it with you.) Name: Date of appointment: Home address:

Lung Cancer. This reference summary will help you better understand lung cancer and the treatment options that are available.

New England Pain Management Consultants At New England Baptist Hospital

Research commissioned by MIB

ASBESTOS-RELATED DISEASES

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group

CMF: Cyclophosphamide, Methotrexate and Fluorouracil

Step 1: Complete the attached Health Appraisal and Medical History Questionnaire, Goal Inventory, and Liability Waiver.

Facing Lung Cancer? Learn why da Vinci Surgery may be your best treatment option for lung cancer.

ORTHOPAEDIC SPINE PAIN QUESTIONNAIRE

Therapies for Treatment- Resistant Depression. A Review of the Research

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

Patient Information. Date: Date of Birth: / / Name: Social Security: _- - Address: Street City State Zip

Stocktake of access to general practice in England

Talking With Your Doctor About Multiple Myeloma: A guide to making the most of your healthcare visits

Lung Cancer. Know how to stay strong

Be cancer aware. Patient Information

Transcription:

Promoting Early Cancer Presentation Group Nature and duration of symptoms of cancers of the lung: report of a study of nature and duration of symptoms Fiona Warburton, Lindsay Forbes November 2013 1

Introduction The 2010 Cancer Patient Experience Survey included 2545 lung cancer patients with ICD-10 code C340 to C349 who agreed they could be re-contacted for further research. One thousand two hundred and thirty (48.3%) of these were known to be alive at the start of survey fieldwork for the study of nature and duration of cancer symptoms (9 Nov 2011). Two hundred patients were randomly selected from these and sent a questionnaire about the nature and duration of their symptoms. Of these 200 a further 16 died and 142 (77.2%) returned a completed questionnaire. All respondents had been diagnosed in the year before the 2010 Cancer Patient Experience Survey. Demographic characteristics of patients Ethnicity was available for 130 participants. One hundred and twenty six (88.7% of the sample) described their ethnicity as White. Age at diagnosis was available for 137 patients. The mean age at diagnosis was 64.9 years, with the youngest being 19 and the oldest 94 at the time of diagnosis. Route to diagnosis Ninety one (64.1%) were referred to hospital by their GP, 13 (9.2%) via A&E, and 32 (22.5%) via another route. There were no data on this available for six patients Symptoms that led to diagnosis Table 1 shows the symptoms reported by the 130 patients who reported any symptoms. The most common symptom was cough (58, 44.6%). Table 1: Reported symptoms leading to diagnosis lung cancer patients Symptom n (%) Cough 58 (44.6) Shortness of breath 44 (33.8) A chest infection that didn t go away 37 (28.5) Pain in chest or shoulder 27 (20.8) Extreme fatigue or tiredness 24 (18.5) Coughed up blood 17 (13.1) Unexpected weight loss 14 (10.8) Croaky voice 8 (6.2) Swelling in face or neck 3 (2.3) Other 40 (30.8) 2

Fifty one participants reported one symptom only. Table 2 shows the symptoms they reported. Table 2: Symptoms of those who reported one symptom only lung cancer patients Symptom n (%) A chest infection that didn t go away 10 (19.6) Cough 7 (13.7) Coughed up blood 7 (13.7) Shortness of breath 5 (9.8) Pain in chest or shoulder 5 (9.8) Swelling in face or neck 2 (3.9) Unexpected weight loss 1 (2.0) Extreme fatigue or tiredness 0 (0.0) Croaky voice 0 (0.0) Other 14 (27.5) Reasons for not going to the doctor Of the 130 patients who reported at least 1 symptom, 59 (45.4%) reported that something had put them off going to the doctor. The most common reason (55, 42.3%) was not realising the symptom was serious. Table 3 shows the frequency of reporting for each of specific barriers to symptomatic presentation. These were relatively rarely reported. Table 3: Reported barriers to symptomatic presentation lung cancer patients Barrier reported n (%) I was worried about wasting the doctor s time 8 (6.2) It was difficult to make an appointment with the doctor 8 (6.2) I had too many other things to worry about at the time 2 (1.5) I was too busy to make time to go to the doctor 2 (1.5) I was too scared to go and see the doctor 2 (1.5) I was too worried about what the doctor might find 2 (1.5) I found my doctor difficult to talk to 2 (1.5) I didn't feel confident talking about my symptoms with the doctor 1 (0.8) I was too embarrassed to go to see the doctor 0 (0.0) It was difficult to arrange transport to the doctor s 0 (0.0) Duration of symptoms For the 130 patients who reported any symptoms, duration of symptoms was calculated using the question How long was it from the time you noticed these MAIN health problems or symptoms and first seeing a GP or hospital doctor? For those patients for whom this information was not available (n=12) we used the time between the symptom first starting and seeing a GP or presenting at accident & emergency, where a full date had been given at both time points, to calculate duration of 3

symptoms. We were able to calculate duration of symptoms for 119 out of the 130 patients who reported any symptoms (91.5%) In total, 13 (10%) delayed presentation by more than 3 months. Table 4 shows the reported duration of symptoms. The numbers in the table are small and therefore the percentages should be interpreted with caution. Those with other symptoms are not included in the table. Table 4: Reported duration of symptoms breast cancer patients, by symptom 4 weeks or less > 4 weeks but <3 months > 3 months missing N (%) N (%) N (%) N (%) Extreme fatigue or tiredness 9 (37.5) 5 (20.8) 5 (20.8) 5 (20.8) Pain in chest or shoulder 13 (48.1) 6 (22.2) 5 (18.5) 3 (11.1) Cough 26 (44.8) 20 (34.5) 8 (13.8) 4 (6.9) Shortness of breath 18 (40.9) 15 (34.1) 6 (13.6) 5 (11.4) A chest infection that didn t go away 22 (59.5) 9 (24.3) 5 (13.5) 1 (2.7) Unexpected weight loss 8 (57.1) 3 (21.4) 1 (7.1) 2 (14.3) Coughed up blood 10 (58.8) 4 (23.5) 1 (5.9) 2 (11.8) Croaky voice 6 (75.0) 1 (12.5) 0 (0.0) 1 (12.5) Swelling in face or neck 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) Risk factors for delay in presentation Table 5 shows the proportion delaying presentation for three months or more by age, gender, index of multiple deprivation (IMD), symptom and whether or not they realised the symptom was serious. It was not possible to calculate adjusted relative risks because of small numbers. The results show that the only symptom that was significantly related to delay in presentation was extreme fatigue or tiredness. There was relationship between delay in presentation and not realising the symptom was serious. Very few patients reported barriers to symptomatic presentation and therefore we did not analyse their association with delay in presentation. 4

Table 5: Risk factors for delay in symptomatic presentation among breast cancer patients reporting any symptoms Age Delay in presentation Relative risk for delay in presentation (95% CI) n (%) Unadjusted <70 (reference) 11/80 (13.8) 1 00 70+ 2/35 (5.7) 0.42 (0.10 to 1.78) Gender Male 7/66 (10.6) 1.00 Female 6/53 (11.3) 1.07 (0.38 to 2.99) Deprivation group Least deprived (reference) 1/12 (8.3) 1 00 3/28 (10.7) 1.29 (0.15 to 11.15) 6/26 (23.1) 2.77 (0.37 to 20.53) 2/30 (6.7) 0.80 (0.08 to 8.02) Most deprived 1/23 (4.3) 0.52 (0.04 to 7.63) Extreme fatigue or tiredness 5/19 (26.3) 3.29 (1.21 to 8.98) Pain in chest or shoulder 5/24 (20.8) 2.47 (0.89 to 6.89) Cough 8/54 (14.8) 1.93 (0.67 to 5.54) Shortness of breath 6/39 (15.4) 1.76 (0.63 to 4.88) A chest infection that didn t go away 5/36 (13.9) 1.44 (0.51 to 4.10) Unexpected weight loss 1/12 (8.3) 0.74 (0.11 to 5.23) Coughed up blood 1/15 (6.7) 0.58 (0.08 to 4.13) Croaky voice 0/7 (0.0) undefined Swelling in face or neck 0/3 (0.0) undefined Did not realise symptom was serious 7/35 (20.0) 2.80 (1.01 to 7.74) 5